According to TipRanks.com, Matson is a 4-star analyst with an average return of 5.0% and a 51.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $50.17 average price target, a 15.2% upside from current levels. In a report issued on April 18, Leerink Partners also maintained a Hold rating on the stock with a $45.00 price target.
The company has a one-year high of $47.50 and a one-year low of $37.96. Currently, Boston Scientific has an average volume of 8.96M.
Based on the recent corporate insider activity of 172 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corporation engages in the manufacturing of medical devices and products that are used in various interventional medical specialties worldwide. The company provides implantable devices including heart monitors, technologies for treating coronary artery disease and other cardiovascular disorders, and devices for diagnosing and treating gastrointestinal and pulmonary problems.
Read More on BSX:
- RBC Capital Thinks Mercedes-Benz Group’s Stock is Going to Recover
- MKS Instruments (MKSI) Received its Third Buy in a Row
- Biocept (BIOC) Receives a Buy from Brookline Capital Markets
- Analysts Conflicted on These Technology Names: Seagate Tech (STX) and Teradyne (TER)
- Waste Management: Throwing Recession Fears in the Garbage